Immunocore Holdings (STU:6YG) Current Accrued Expense : €105.2 Mil (As of Mar. 2025)

View and export this data going back to 2021. Start your Free Trial

What is Immunocore Holdings Current Accrued Expense?

Immunocore Holdings's Current Accrued Expense for the quarter that ended in Mar. 2025 was €105.2 Mil.

Immunocore Holdings's quarterly Current Accrued Expense declined from Sep. 2024 (€165.7 Mil) to Dec. 2024 (€164.7 Mil) and declined from Dec. 2024 (€164.7 Mil) to Mar. 2025 (€105.2 Mil).

Immunocore Holdings's annual Current Accrued Expense increased from Dec. 2022 (€62.8 Mil) to Dec. 2023 (€99.3 Mil) and increased from Dec. 2023 (€99.3 Mil) to Dec. 2024 (€164.7 Mil).

Immunocore Holdings Current Accrued Expense Historical Data

The historical data trend for Immunocore Holdings's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immunocore Holdings Current Accrued Expense Chart

Immunocore Holdings Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Current Accrued Expense

Get a 7-Day Free Trial

21.65

32.71

62.75

99.25

164.67

Immunocore Holdings Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Current Accrued Expense	Get a 7-Day Free Trial															117.06	143.20	165.73	164.67	105.16

Immunocore Holdings Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

Immunocore Holdings Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of Immunocore Holdings's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Immunocore Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunocore Holdings PLC (STU:6YG) » Definitions » Current Accrued Expense

Comparable Companies

Traded in Other Exchanges

IMCR:USA

Address

92 Park Drive, Milton Park, Abingdon, Oxfordshire, GBR, OX14 4RY

Website

https://www.immunocore.com

Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.

Immunocore Holdings Headlines

No Headlines